NeoGenomics (NEO), Why Is Its Latest Update Drawing Attention?
Why NeoGenomics’ latest quarter caught investors’ attention
NeoGenomics (NEO) moved into focus after a Q2 report showing revenue up 11.2% year on year and earnings per share slightly ahead of expectations. Management highlighted consistent operating and financial performance, which helped support recent investor interest.
The recent Q2 update landed after a powerful run in NeoGenomics’ shares, with a 90-day share price return of 55.34% and a 1-year total shareholder return of 117.59%. The latest 1-day and 7-day moves have eased slightly, hinting that the strongest near term momentum may be cooling even as the longer term trend remains firmly positive.
Scan beyond NeoGenomics’ strong quarter and see how other hand picked healthcare names with solid fundamentals stack up in our list of solid balance sheet and fundamentals (23 results).
Bulls see NeoGenomics’ jump and recent revenue and earnings beats as the start of a sustained rerating. Bears point to ongoing losses and a sharp 1 year surge. Which story does the valuation support next?
Most Popular Narrative: 12.2% Undervalued
NeoGenomics closed at $17.32 while the widely followed narrative pegs fair value closer to $19.72, which puts a lot of weight on future profitability and pricing power.
Investments in new digital pathology capabilities, automation, and the integration of a unified LIMS are expected to generate material operating efficiencies and enable greater operating leverage, supporting future expansion in EBITDA margins and earnings growth.
Read the complete narrative. Read the complete narrative.
Want to see what kind of revenue lift, margin shift, and future earnings profile are included in that near $20 fair value for NeoGenomics? The narrative leans on a specific glide path for test volumes, profitability, and the multiple the market might one day pay for those earnings. The detail behind those inputs is where the real story sits.
Result: Fair Value of $19.72 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, the narrative around NeoGenomics can change quickly if competition in oncology diagnostics squeezes pricing, or if litigation and high fixed costs pressure already loss making results.
Find out about the key risks to this NeoGenomics narrative.
Another View on NeoGenomics’ valuation
The story looks different when you move from that near $20 fair value to simple sales multiples. NeoGenomics trades on a P/S ratio of 2.9x, almost double both the US Healthcare industry average of 1.4x and its own fair ratio of 1.6x, which points to meaningful valuation risk if sentiment cools.
For investors trying to weigh that gap between current pricing and the fair ratio, the numbers driven breakdown in our valuation workup on NeoGenomics can help you stress test your own expectations. See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Impressed by NeoGenomics’ recent run or cautious about the risks that still hang over the story, either way you should pressure test the data yourself and weigh how the 2 important warning signs fits into your view.
Looking for more investment ideas beyond NeoGenomics?
If NeoGenomics has sharpened your focus, do not stop there. Use the Simply Wall Street Screener to spot other opportunities before the crowd catches on.
- Target reliable income by scanning for companies that resemble durable income engines through the 6 dividend fortresses.
- Hunt for potential mispriced opportunities by focusing on financially strong businesses in the 31 high quality undervalued stocks.
- Stack the odds toward capital preservation by filtering for companies with steadier profiles using the 11 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com